Molecular Imaging, Inc. Announces New Webinar: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging
Molecular Imaging, a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, is sponsoring a webinar to examine new imaging strategies that can facilitate the discovery and clinical use of new therapeutics and diagnostics.
Ann Arbor, MI (PRWEB) September 05, 2013
The free webinar, which will take place on September 10, 2013 at 11am ET, will feature presentations by Patrick McConville, Chief Scientific Officer of Molecular Imaging, and Maria Vosjan of BV Cyclotron VU.
Dr. McConville will review the dual labeling and imaging strategy and related challenges. He will provide an overview of the key imaging technologies involved, and how these technologies can be accessed and used to drive key decision-making associated with assessment of biologics targeting and biodistribution. Dr. Vosjan will present an overview of immuno-PET imaging of targeting and non-invasive biodistribution. She will focus on zirconium-89 and iodine-124 PET based detection and imaging of labeled antibodies, including preclinical and clinical imaging success stories.
“In vivo biodistribution imaging studies are increasingly enhancing the discovery and development of new biologic and pharmaceutical molecules. Attendees of this webinar can expect to gain a greater understanding of the need, challenges, and execution of the imaging in these biodistribution studies including PET, SPECT, and in vivo fluorescence tomography," said Molecular Imaging CSO, Patrick McConville.
Tuesday, September 10, 2013
Duration: 1 hour
Click here for additional information and to register.
About Molecular Imaging, Inc.
Molecular Imaging, Inc. is a specialty contract research organization (CRO) located in Ann Arbor, Michigan. Molecular Imaging employs a wide array of imaging technologies, including MRI, micro-CT, micro-PET, SPECT and optical (two-dimensional and fluorescence molecular tomography) to quantitatively assess test agent performance at anatomical, functional and molecular levels. Molecular Imaging Inc. also conducts applications research to develop and optimize the use of imaging and actively seeks collaborations to further advance imaging in the field of drug discovery.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11088655.htm